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Expression quantitative trait loci (eQTL) have become an attractive research
topic in the past decade assisted by the technical advances in next-generation
sequencing (NGS) and high-throughput gene expression measurements. eQTL
discoveries provided researchers with new insights into genetic regulatory
mechanisms, and are crucial in establishing functional links in genome-wide
association study (GWAS) results. A powerful aspect of these studies are that
the simultaneous genome wide measurements of gene expression values and
sequence variants make it possible to detect associations independent of prior
knowledge. However, the high dimensionality of the data also creates multiple
challenges in the analysis process. Population structure in genotype data can
induce significant inflation in the results leading to false positive findings, and
confounding factors in gene expression measurements, such as technical batch
effects and environmental differences, can lower the detection power of small
genetic effects.
The focus of this thesis is on the challenges in analyzing high-dimensional
gene expression data to increase the accuracy in eQTL discovery. A central prob-
lem in developing confounding factor correction methods for eQTL analysis is
to account for non-genetic confounding factors, while preventing broad impact
genetic effects of being modeled as non-genetic variation. To address this is-
sue, we developed a novel method CONFETI: CONfounding Factor Estima-
tion Through Independent component analysis. CONFETI is based on a linear
mixed model framework and uses independent component analysis (ICA) to
estimate statistically independent generative sources from the observed gene
expression profiles. Candidate genetic effects are excluded from the correction
to maximize the discovery of broad impact eQTL, using the estimated indepen-
dent components. We evaluated our framework by comparing the performance
to other published confounding factor correction methods using both simulated
and real human data.
In the analysis of simulated data, we show that CONFETI most accurately
recovered simulated eQTL results in the presence of confounding factors by
distinguishing genetic effects from non-genetic variance. We then analyzed
matched twin pair datasets from the Multiple Tissue Human Expression Re-
source (MuTHER) consortium and datasets consisting of similar tissue pairs
from the Genotype-Tissue Expression (GTEx) consortium. To assess the per-
formance of each method in human data, we investigated the replication of cis
and trans-eQTL identified in each dataset. We found that accounting for con-
founding factors greatly increased both the number of identified cis-eQTL in
each dataset, and replicating cis-eQTL between twin pairs and similar tissue
types. The number of identified trans-eQTL increased as well, however, most
of the findings were specific to each dataset and the replication rate remained
significantly lower compared to cis-eQTL. While the use of confounding factor
correction methods increased the power of the analysis, we found little differ-
ence in identifying replicating cis and trans-eQTL in human data by removing
candidate genetic effects prior to correction.
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CHAPTER 1
INTRODUCTION
Technical advances in measuring genome-wide genetic variation, including
single nucledotie polymorphism (SNP) arrays and next-generation sequencing
(NGS) techniques, transformed the field of genetics and introduced us to the
genomics era. We moved from investigating the genome with linkage analy-
sis and candidate-gene based methods to hypothesis generating Genome-wide
Association Studies (GWAS) [1]. The concept of GWAS was formulated after
the discovery of linkage disequilibrium (LD) blocks, which are local correla-
tion structures in the genome that are inherited together. While it is difficult to
measure the exact causal polymorphism without the use of whole genome se-
quencing, LD blocks led to the revelation that it is possible to proxy the causal
polymorphism by having a subset of marker SNPs throughout the genome [2].
In a typical GWAS, the association between genome-wide sequence variations
and a trait of interest is tested. Ever since the first GWAS in 2005 [3], GWAS re-
sults have been at the forefront of identifying genomic regions associated with
specific traits of interest, such as common diseases and phenotypes including
height and body mass index (BMI). As of 2016, the GWAS catalog [4] contained
2,650 study results and 29,954 unique SNP-trait associations for various dis-
eases and complex traits. In addition to prioritizing genes or genomic regions
in studying specific traits, GWAS results can be used to reveal valuable insights
related to the genetic architecture by estimating the heritability and effect size,
and by identifying genetic interactions such as epistasis or pleiotropy [5].
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However, despite the vast amount of accumulated knowledge generated by
GWAS results, little is known about the underlying biological mechanisms in
these findings [6]. Part of the reason stems from the fact that most GWAS find-
ings fall within non-coding regions of the genome, making it difficult to draw
direct conclusions of their biological impact [7]. Additionally, differences in
gene regulation between tissues and cell types make it challenging to inves-
tigate the biological pathways relevant to the genomic regions of interest. One
way to address this problem is to integrate information from GWAS results with
that of gene regulatory regions identified by expression Quantitative Trait Loci
(eQTL) analyses.
1.1 Expression Quantitative Trait Loci
eQTL are genomic sequence variants that influence the expression level of sin-
gle or multiple genes [8]. These can be identified by testing the association be-
tween measured sequence variants, generally SNPs, and gene expression lev-
els measured by microarray or RNA-sequencing (Figure 1.1). Basically, eQTL
can be considered as multiple GWAS analyses where the trait of interests are
gene expression levels. The current genome-wide picture of the genetics of
gene expression in humans has been driven by eQTL studies in various pop-
ulations and cell types [9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22]. Findings
in eQTL studies are routinely leveraged to identify candidate disease risk loci
within regions associated with complex diseases in GWAS. This process is based
on the assumption that when an eQTL co-locates with a locus identified in a
GWAS, the same allelic variants are impacting both gene expression and disease
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risk [23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45].
Genome-wide eQTL discovery has also provided a foundation for inferences
about biological systems. For example, eQTL are used within data aggregation
methods to annotate the functional or fitness impacts of polymorphisms [46],
which in turn is a main component of systems biology models of pathways and
cellular processes [47, 48, 49, 50, 51]. eQTL are also used for network modeling,
in large part because eQTL can be used to model a directed impact on gene
expression, which in turn can be leveraged to infer other directed network rela-
tionships among expressed genes [52, 53, 54, 55].
Such eQTL discovery approaches have led to a number of generalizations
about the genetics of gene expression and regulation at genome-wide scales [11,
56]. These include observations that the majority of genes in the genome can
be impacted by an eQTL [57], that eQTL proximal to the regulated gene have
significantly larger effect sizes than distant eQTL [18, 30, 58], and that eQTL can
have tissue specific impacts on an expressed gene [34, 59].
1.1.1 cis-eQTL and trans-eQTL
eQTL can be broadly classified into cis-eQTL and trans-eQTL based on the dis-
tance between the genotype and associated gene location. Albeit varying princi-
ples, eQTL are generally considered cis if the genotype and the associated gene
are located on the same chromosome within a 1Mb distance, and trans other-
3
Figure 1.1: Illustration of eQTL
eQTL are sequence variants in the genome that are associated with expression
level changes of specific genes. A typical eQTL analysis tests the association
between approximately 600,000 genotypes and 20,000 gene expression
measurements.
wise [18, 56]. Other classification methods have been proposed to account for
allele specific effects [8,37]. However, this thesis will only consider the distance
based categorization.
Due to the large number of possible genotype-expression variable pair com-
parisons in human eQTL studies, which can range from 109 − 1010 for array
based studies [15] and 1011 − 1012 for data collected by next-generation sequenc-
ing technologies [20], it is common to reduce the multiple testing burden by
only considering a subset of genotype-expression pairs. Therefore, many stud-
ies have primarily focused on identifying cis-eQTL by only testing genotypes
and phenotypes that are within a certain distance [11,15,17,22]. A consequence
of such strategies is that well defined characteristics for cis-eQTL have been es-
tablished, such as enrichment near transcription start sites and large effect size,
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but relatively little is known about trans-eQTL. While more recently trans-eQTL
also came into focus [18, 21, 30, 60], the number of identified trans-eQTL remain
modest and evidence for replication varies [61]. It is hypothesized that the de-
tection and replication of trans-eQTL is difficult partly due to their tissue or
condition specific functionalities [59, 62].
1.1.2 Broad Impact eQTL
When considering associations with complex diseases, eQTL that affect many
genes have been hypothesized to have effects beyond the transcriptome and
are therefore good candidates for investigating downstream disease pheno-
types [63]. Such broad impact eQTL [21], variously referred to as eQTL hotspots
[8], master regulators [60], trans-regulators [64], and trans-eQTL networks [65]
could result from either hotspots of multiple co-located eQTL [8,66] or from the
pleiotropic effects of a single eQTL genotype [37].
For studies that leverage eQTL as a foundation for network modeling or for
identifying candidate disease risk loci, eQTL that are associated with multiple
genes can be particularly valuable. Additionally, the value of such broad impact
eQTL is clear for directed network modeling, since the network inference de-
pends on tracking the impact of eQTL through multiple genes [67,68,69,70,71].
Broad impact eQTL have regularly been observed in model organisms such as
yeast [72, 73, 74] and mice [75], but have been reported less frequently and in
smaller numbers in human eQTL studies [8]. Based on observations that broad
impact eQTL are expected to primarily affect trans-genes, statistical power has
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been suggested as a possible reason for the relatively lower reporting of broad
impact eQTL in humans, since trans-eQTL tend to have relatively weak associa-
tions in humans compared to model organisms [8]. Additionally, methods that
account for unknown confounding variance have the potential to incorrectly
explain away the effect of broad impact eQTL [76, 77].
1.2 Challenges in eQTL Analyses
1.2.1 Lack of Standardization
The rapid advance in genotyping and gene expression measurement technolo-
gies have undoubtedly benefited the field of human genetics through the find-
ings of eQTL studies. However, since the advancement in technology is still
an ongoing process, for many eQTL studies the platforms for measuring gene
expression and genotyping are different making it difficult to combined multi-
ple datasets. It is common that the set of measured SNPs are different and that
missing SNPs need to be imputed based on the available information. For gene
expression measurements, microarrays generally have fewer genes measured
compared to RNA-seq since they require capture probes, and both techniques
are influenced by different technical artifacts. Finally, most of the analysis meth-
ods are unique to each study making it difficult to directly compare the results
of multiple studies. Therefore, comparing results between different datasets are
largely achieved by re-analyzing entire datasets with a centralized pipeline.
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1.2.2 Population Structure
To detect eQTL with relatively small genetic effect sizes, a large number of sam-
ples are required for an association study. Therefore, it is common for stud-
ies with large scale datasets to have samples originating from multiple popula-
tions [15, 20, 22, 78]. In analyzing these samples consisting of different popula-
tions, accounting for population structure is a critical step to control the number
of false positive findings. The presence of broad genetic similarity between sam-
ples can be problematic because an imbalance in the measured expression levels
between populations could lead to all SNPs that are correlated to the respective
populations being called significant [79]. While this difference could be origi-
nating from a true genetic effect specific to populations, more commonly it will
greatly increasing the number of false positives due to spurious correlations.
Various methods that estimate and control for the genetic relatedness structure
between samples have been proposed in GWAS studies [80, 81, 82, 83, 84, 85].
The most commonly applied method is to include a select number of genotype
principal components in the model [81], which has also been widely used when
conducting eQTL analysis [20, 22].
1.2.3 Confounding Factor Effects
Consortium scale studies in which samples from multiple populations are pro-
cessed across multiple laboratories are becoming the norm in eQTL datasets
[18, 20, 22]. Additional to accounting for population structure, a particularly
important aspect in analyzing these datsets is to correct for structures in the
7
samples arising due to non-genetic confounding factors that violate the inde-
pendence assumption of the model. It has been shown that samples, which
have been processed across different institutions or using different protocols,
can be impacted by systematic variance that influence a large fraction of ex-
pressed genes. For example, factors such as non-specific binding due to probe
design, and environmental differences such as atmospheric ozone levels [86]
can be problematic in microarrays, while in RNA-seq GC content and insert
size variations in the libraries can affect measurements [87]. If not correctly ac-
counted for, these confounding factor effects can lower the power of the analysis
by masking real genetic effects, and can also induce false positive results. Multi-
ple groups have developed methods to estimate and correct for these confound-
ing factor effects in eQTL analyses [66, 76, 77, 88, 89, 90, 91]. It has been shown
that these increase the number of identified eQTL in practice. These methods
can be broadly categorized into two groups.
Linear Fixed Effect Model The first group of methods attempt to model the
confounding factor effects using certain assumptions about the factors and in-
clude the estimated covariates as fixed effects for correction [76,88,90,91]. In the
basic linear fixed effect model, which is the most widely used method for map-
ping eQTL, the expression level of a single gene ~y for n individuals is modeled
as linear combinations of genetic effects and covariates as
~y = X~βx + Z~βz + ~ (1.1)
where ~y is an n × 1 vector of gene expression values, X is an n × g matrix of g
genotypes and ~βx is an g×1 vector of genotype coefficients. Z is an n× f matrix of
f covariates and ~βz is a f × 1 vector of covariate coefficients. Here, confounding
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factors are commonly estimated using the full expression matrix Y, which spans
the expression values ~y for every gene, and the estimated effects are modeled in
Z. Methods including principal component analysis (PCA) [88], factor analysis
(FA) [76,91], and independent component analysis (ICA) [90] have been used in
previous approaches to estimate confounding factors. Additional factors such
as age, gender, and experimental batches, are also often included as covariates
to account for their influence on expression level. Due to its closed form solu-
tion and simplicity, the linear fixed effect model has a very low computational
cost and is relatively easy to interpret. However, as the number of parameters
increase the statistical power of the model is reduced and there is also the po-
tential of over correction.
Linear Mixed Model The second group of methods attempt to model a co-
variance structure between samples and include this information as a random
effect in a linear mixed model [66,77,89]. The main advantage of a linear mixed
model is that it can model dependent structures between samples, which can be
problematic under the assumption of independence. Additionally, linear mixed
models do not suffer from the loss of power due to additional parameters. In
a linear mixed model framework, a random effect that accounts for correlation
structures in the samples is used in addition to the fixed effects.
~y = X~βx + ~c + ~ (1.2)
~c ∼ N(~0, τ2K) (1.3)
~ ∼ N(~0, σ2I) (1.4)
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Here, ~y is an n×1 vector of gene expression values, X is an n×g matrix of g geno-
types and ~βx is an g×1 vector of genotype coefficients. ~c is an n×1 random effect
vector which is assumed to be sampled from a multivariate normal distribution
with mean ~0, and covariance τ2K. ~ represents the random noise drawn from a
multivariate normal distribution with mean ~0 and covariance σ2I.
The key difference between confounding factor methods using this approach
is the estimation of the n×n sample covariance matrix K. Strategies from simply
taking the covariance matrix of Y [66], to estimating K in a maximum likelihood
framework [77, 89] have been used in previous studies. One particular concern
in the application of linear mixed models in eQTL is that unlike the fixed ef-
fect model the linear mixed model does not have a closed form solution mak-
ing the estimation of parameters more difficult. To address this issue, several
approaches that increase the computational efficiency of parameter estimation
have been proposed [82, 92].
1.3 Overview of Dissertation
In this thesis, we focus on analyzing gene expression profiles to estimate expres-
sion patterns that can be utilized to increase the accuracy of eQTL discovery in
human datasets. Specifically, we use independent component analysis (ICA) to
identify patterns in gene expression data and apply our findings to develop a
linear mixed model confounding factor correction method. First, we introduce a
new software tool that facilitates the application of ICA to gene expression data
in chapter 2. In chapter 3 we describe CONFETI, a novel confounding factor
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correction method we have developed, that specifically addresses the problem
of estimating broad impact genetic effects. We then apply CONFETI to sim-
ulated data where we know the generative truth to evaluate the performance
of CONFETI in comparison to other confounding factor correction methods in
chapter 4. Finally, in chapter 5 we apply CONFETI and other confounding fac-
tor correction methods to a collection of human eQTL datasets and investigate
the replication of eQTL as a measure of performance.
1.3.1 Analyzing Gene Expression Data with Independent Com-
ponent Analysis
In chapter 2, we review the concept and applications of the widely used blind
source separation method ICA. We then describe its main strength in ana-
lyzing gene expression profiles in comparison to PCA. Finally, we introduce
picaplot, an R package that we developed for analyzing gene expression data
with ICA. We describe the key features of picaplot including single and multi-
run IC estimation, unsupervised detection of sample clusters, covariate associ-
ation testing, and comprehensive visualization of results. Results obtained by
analyzing publicly available gene expression data are presented to showcase the
usage of picaplot.
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1.3.2 CONFETI: An Independent Component Analysis Con-
founding Factor Correction Framework
In chapter 3, we introduce CONFETI, a novel linear mixed model confound-
ing factor correction method based on ICA. CONFETI is a method designed
to avoid the inclusion of genetic effects in the correction of confounding vari-
ation, thus maximizing the potential of broad impact eQTL discovery. This is
implemented by estimating and filtering out candidate genetic effects from gene
expression data using ICA. The non-genetic expression matrix is then used to
construct a sample covariance matrix, which is used as a random effect in a lin-
ear mixed model framework. We describe the eQTL model in detail and provide
a comparison to other published confounding factor correction methods.
1.3.3 Comparison of Confounding Factor Correction Methods
Using Simulated Data
To first evaluate the performance of CONFETI and compare it to other pub-
lished confounding factor correction methods, we use simulated eQTL data and
analyze the results. We use yeast genotype data to simulate phenotype values
for cis, trans and broad impact eQTL and use CONFETI and other published
methods including PEER, ICE, and PANAMA to analyze the datasets. The re-
sults demonstrate that CONFETI most accurately estimates simulated eQTLs in
the presence of broad impact eQTL and confounding factors. We present the
results showing the overall accuracy of simulated eQTL and the recovery rate
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in each simulated eQTL category.
1.3.4 Evaluating the Performance of Confounding Factor Cor-
rection Methods through Replicating eQTL in Human
Data
In the final chapter, we present the analysis results of human eQTL datasets
using CONFETI and other confounding factor correction methods. Since we do
not have a gold standard eQTL dataset where a set of true eQTL are known to
us, we focused on assessing the replication of cis and trans-eQTL in the analysis.
For this purpose we used datasets obtained from the Multiple Tissue Human
Expression Resource (MuTHER) consortium, which consisted of matched twin
pairs for three different tissue types (Adipose, LCL, and Skin), and datasets
obtained from the Genotype-Tissue Expression (GTEx) consortium, from which
we selected 4 tissue pairs (Adipose - Subcutaneous and Visceral, Artery - Aorta
and Tibial, Heart - Atrial Appendage and Left Ventricle, Skin - Suprapubic and
Leg).
Accounting for confounding variation led to a significant increase of eQTL
discoveries compared to simple linear regression, with linear mixed model
based methods identifying the largest number of eQTL. However, we found
little difference in identifying eQTL between linear mixed model confounding
factor correction methods that accounted for the majority of the total variance
in constructing the sample covariance matrix. Additionally, while a large frac-
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tion of identified cis-eQTL replicated between twin and tissue pairs and across
all datasets, most of the identified trans-eQTL were dataset specific and did not
replicate well.
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CHAPTER 2
ANALYZING GENE EXPRESSION DATA WITH INDEPENDENT
COMPONENT ANALYSIS
2.1 Introduction
Genome-wide gene expression profiling by RNA-Seq or microarray is a prolific
strategy for discovering novel biological pathways impacted by experimental
treatments [93] and for revealing the impact of genetic variation on gene ex-
pression [41]. With the introduction of microarrays the simultaneous quantifi-
cation of expression levels of many genes became easy, and RNA-seq expanded
the scope by enabling the detection of previously unknown genes and isoforms.
The number of measured genes varies depending on the measurement plat-
forms but generally exceeds 20,000, creating multiple challenges in the analysis
process related to the high-dimensionality.
Critical to drawing correct biological conclusions from the analysis of such
data is pre-analysis detection and correction for systematic differences caused
by measured and unmeasured factors, such as technical batch effects and het-
erogeneous environmental conditions [94]. If not accounted for, these cryptic
factors can often contribute a significant proportion of the total variation in gene
expression data, which can result in obscured signals of experimental impacts or
worse, systematic biases and artifacts that are incorrectly interpreted as biolog-
ical findings. Besides, these factors can potentially lead to interesting biological
findings themselves by revealing differences in pathway activation patterns or
15
cellular states depending on different environments.
The most routinely used method to inspect the data for apparent patterns
prior to analysis is principal component analysis (PCA). In most cases, the
lower dimensional projections of the data onto the first few principal compo-
nents are used to reveal patterns or clusters among samples that explain the
largest amount of variance. While clearly a valuable approach due to the well
defined statistical properties and relatively simple calculations, PCA is likely
to return mixtures of multiple independent factor effects unless these happen
to be aligned with the dimensions of greatest variation in the data [95]. There-
fore, directly interpreting principal components can often be problematic and
misleading. Additionally, by only considering an arbitrary number of compo-
nents, patterns that have lower contribution to the overall variance can easily
be missed.
Independent Component Analysis (ICA), which is a blind source separation
method that decomposes the data into statistically independent components,
can provide a clearer separation of these components. By using a stronger
principle of statistical independence, ICA is expected to return interpretable
components each aligning with an independent factor as long as these factors
are non-Gaussian. ICA has been applied to problems such as voice and im-
age separation, and more recently to high dimensional gene expression data
to estimate non-Gaussian generative sources from an observed mixture. For
example, studies have used ICA on problems such as expression pattern anal-
ysis [96, 97, 98, 99] , tumor classification [95, 100], and analyzing the effects of
genetic variation [101, 102]. Here we propose a gene expression analysis frame-
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work centered on ICA with information about every component to provide a
more accurate, interpretable, and comprehensive estimation of covariate effects.
2.2 The Concept of Independent Component Analysis
Figure 2.1: Composite images
Examples of images created by mixing 4 different source images.
To explore the principles of ICA and how it is applied to gene expression
data, let us first begin with a simple example using image separation. In Fig-
ure 2.1 a collection of images is shown made up of composite images generated
by taking a weighted sum of 4 different 64 x 64 pixel gray scale source images.
The source images used for this example are shown in Figure 2.2(a). Here, the
problem that we are trying to solve with ICA is to estimated the generative
sources from the composite images without any given information about the
source images or the mixture weights. This framework is often referred to as
blind source separation (BSS),since we are attempting to separate sources from
a mixture without prior knowledge.
To explore this in the ICA framework we first need to find a mathematical
representation of our problem. Since each image can be considered as a 4096
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(a) (b) (c)
Figure 2.2: Four gray scale source images
(a) Images of our family dog, the view from my apartment, a world map, and a
new york city pigeon. (b) Pixel brightness values for each image shown in a
scatter plot. (c) Histogram of pixel brightness values for each image.
dimensional vector of pixel brightness values, as shown in Figure 2.2(b), we can
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express each composite image as a linear equation:
~mi = ai1 ~p1 + ai2 ~p2 + ai3 ~p3 + ai4 ~p4 (2.1)
where ~mi and ~pk, with i, k ∈ {1, 2, 3, 4}, are both 4096 dimensional vectors with
the former representing composite images and the latter representing source
images. Values of aik are showing the mixture weights of each image k in each
mixture i.
Given that the mixture coefficients are a unique combination for each mi
without being a scalar multiple of another, one way to estimate each ~pk would
be to find a transformation of the observed ~mi.
~pk = wk1 ~m1 + wk2 ~m2 + wk3 ~m3 + wk4 ~m4 (2.2)
For this strategy to work, an assumption that defines the desired properties of
the resulting ~pk components is required. Without such a criteria to optimize for,
any transformation is going to have equal importance making it impossible to
converge on estimations for ~pk.
In the ICA framework, the two assumptions applied to accomplish this is
that each ~pk are statistically independent of each other and have non-gaussian
distributions. This is based on the properties of the central limit theorem which
states that the sum of independent and identically distributed random vari-
ables will tend to be more gaussian than their respective distributions. Here,
the distributions of the source signals are not necessarily identical, but it has
been shown in variations of the central limit theorem and in practice that this
property still holds even with different distributions [103]. Thus, estimating
the most non-Gaussian components from the observed mixture, we would be
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able to recover the components closest to the source signals. Based on this cri-
terion, ICA estimates the values for wk j that maximizes the non-gaussianity of
the resulting ~pk. To be more specific, ICA will look for an orthogonal projection
matrix W, constructed from values of wk j, that maximizes the non-gaussianity of
the resulting pixel brightness distributions. We can see in Figure 2.2(c) that the
distribution of pixel brightness values are non-Gaussian for the source images,
which enables the application of ICA to this problem. The coefficient values
aik can then be calculated by taking the inverse of W. Figure 2.3 shows the es-
timated source images by ICA in comparison to the PCA results. We can see
that the results obtained by ICA show a clearer separation of the source im-
ages, while the principal components show little difference from the observed
mixtures.
Figure 2.3: Estimated source images by ICA and PCA
The resulting components obtained by applying ICA (top row) and PCA
(bottom row) to the image mixtures.
Similar to the image mixture example, we can project the idea directly to
gene expression profiles. We hypothesize that each expression profile of a single
sample i is a combination of multiple independent components, which can be
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either genetic or non-genetic components.
~yi = ai1 ~s1 + ai2 ~s2 + · · · + aik ~sk =
k∑
j=1
ai j~s j (2.3)
where ~yi is a vector of g gene expression values for a single sample, and ~s j are
g-dimensional independent components of gene weights that are shared among
all samples and the scalar component coefficients ai j represent the contribution
of each independent component ~s j for sample i. In this case, the estimation of
independent components will depend on the assumption that gene weight dis-
tributions of each ~s j are non-gaussian. This is not an unreasonable assumption,
since most biological processes will be strongly driven by a subset of the total
genes resulting in super gaussian distribution, and non-genetic effects such as
batch effects have a tendency to have a broad impact thus resulting in a heavy
tailed distribution.
There are several algorithms that use different approaches to perform ICA,
such as maximum likelihood estimation [104], high-order correlations opti-
mized by Jacobi algorithms [105], reproducing kernel Hilbert space based ap-
proach [106], and estimation based on efficient entropy estimation [107]. In this
thesis, we used the well studied FastICA algorithm [108] for efficient and ro-
bust computations, which uses an approximation of negentropy as a measure
of statistical independence.
Here we briefly review the estimation of negentropy used as an approxi-
mation of non-gaussianity which is used in the FastICA algorithm [108]. Ne-
gentropy is a measure of the departure of a given distribution from a gaussian
random variable with the same mean and variance (or covariance structure). It
is based on differential entropy H, which for a random variable x with density
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px can be shown as
H(x) = −
∫
px(η) log px(η)dη (2.4)
This can be considered as a measure of average surprisal of a random variable,
or a measure of how structured a random variable is. It takes a small value
when a variable is more predictable and structured, for example if the prob-
ability of the majority lies close to 0 or 1. It has been shown in information
theory that for random variables of equal variance, a gaussian variable is the
least structured with the largest entropy [103]. Based on this result, we can use
the difference between the differential entropy of a given random variable and
a gaussian variable with equal variance as a measure of non-gaussianity. This
measure is called negentropy and is defined as
J(x) = H(g) − H(x) (2.5)
where g is a gaussian random variable with var(x). Since the gaussian variable
will always have the maximum differential entropy, negentropy will always be
positive for a non-gaussian x, and 0 if x is gaussian. Despite having a statistical
justification negentropy is difficult to calculate computationally since it needs an
estimate of the probability density function. Thus, an approximation of negen-
tropy based on higher order statistics is used. Hyvarinen proposed an approach
that uses a generalized form of higher-order cumulant approximation, in which
negentropy is approximated by
J(x) ∝ [E{G(x)} − E{G(g)}]2 (2.6)
where the following nonquadratic functions G with 1 ≤ a1 ≤ 2 are suitable
choices [109].
G1(x) =
1
a1
log cosh a1x (2.7)
G2(x) = − exp(−x2/2) (2.8)
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After a nonquadratic function is selected, the FastICA algorithm finds a projec-
tion matrix that maximizes the negentropy using a fixed-point iteration scheme.
While it is possible to estimate components one at a time, this could lead to
cumulated errors in the components estimated later in sequence. Therefore,
we chose the simultaneous estimation of components, which estimates a given
number of components in parallel.
2.3 picaplot: an R package for Identifying Cryptic Covariates
in Genome-Wide Gene Expression Data
For the specific purpose of applying ICA to gene expression data, we devel-
oped a publicly available R package picaplot. The key features of picaplot
include simple application of ICA to gene expression data, automated cluster
detection to identify cryptic covariate effects and interpretable outputs that are
easy to incorporate as fixed effects in analyses using linear models. The package
also implements parallel functionality for PCA to compare the results with that
of the ICA output.
2.3.1 Single-run and Ensemble ICA Estimation
The observed expression values Y are assumed to be linear combinations of
non-Gaussian statistically independent components and are decomposed into a
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mixing matrix A and component matrix S:
Y = AS (2.9)
whereY is an n×g matrix with expression values for n individuals and g genes. A
is an n×k mixing matrix with k component coefficients for each sample, and S is
a k×g independent component matrix with g gene weights for each component.
The number of components k has to be set prior to decomposition and
picaplot provides two ways to estimate k. The first approach is based on the
% variance explained by principal components. The user can either directly set k
or can provide the amount of variance to be included and picaplot will auto-
matically determine the number of components based on the % variance. When
neither k nor the % variance are provided by the user, the run ica() function
will automatically use the number of principal components that explain a 99%
of the total variance by default.
In the second approach, run ica() is executed multiple times and the sim-
ilarity between components is estimated based on the gene weights of S in each
run. This is to address the problem of unstable results obtained from a single
estimation of ICA. Since the optimization process begins with a random initial-
ization of the projection matrix, there is a possibility that local maximums could
lead to different results in each run. One way to estimate the similarity between
components is to calculate the pair-wise correlation of each component. How-
ever, given the high-dimensionality of the components this could lead to a sys-
temic underestimation of correlation values in cases where there are only few
genes that have a significant gene weight. Therefore, the recommended way of
calculating the similarity between components is to only use the gene weight
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values of ”peaks”, which are gene weights that are greater than 2 standard de-
viations of the corresponding component gene weight distribution. Based on
the calculated similarity the estimated components are grouped together by hi-
erarchical clustering, and clusters with a total number of components exceeding
90% of the number of runs are selected. For example, if ICA was performed 10
times, clusters with more than 9 components are considered as replicating. This
arbitrary threshold can be set by the user, however we recommend a stringent
threshold for robust estimation of replicating components. The average of com-
ponent gene weights within each replicating cluster are then used to generate
an ensemble estimate of replicating components.
2.3.2 Covariate Association Checking
The covariate association check() function can be used on the ICA
decomposition results to identify associations between the IC coefficients
(columns of A) and measured covariates. Since IC coefficients show the rela-
tive contribution of each IC in each sample, this information can link estimated
ICs to measured variables of interest. For example, this could estimate the ef-
fects of commonly included covariates such as age, gender and experimental
batches. Moreover, if covariates for experimental treatments are available the
association analysis could reveal ICs related to specific biological pathways.
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2.3.3 Cluster Detection in IC coefficients
For cases where covariate measurements are limited or not present, we have
included a feature for model-based clustering to detect distinct clusters in the
IC coefficients. This could potentially reveal interesting structures that sepa-
rate samples into different groups without the need of any measured labels or
traits. This can be particularly useful in cases where unmeasured differences
in sample processing steps or unknown environmental differences have sys-
tematic influences on the expression measurements of genes. Implemented in
the detect clusters() function, the feature is based on functionalities of
the mclust R package [110]. It uses an Expectation-Maximization (EM) algo-
rithm to perform a maximum-likelihood estimation of parameterized Gaussian
mixture models on the univariate IC coefficient data for each component, and
selects the ideal model based on the Bayesian Information Criterion (BIC) [111].
In other words, it fits different numbers of Gaussian distributions using the IC
coefficient estimates of each component and finds the number of Gaussian dis-
tributions that best explain the data. The function returns the estimated number
of clusters for each IC coefficient with their corresponding cluster labels if mul-
tiple clusters are estimated.
2.3.4 Correcting IC Effects in Linear Models
To include the IC coefficients associated with known covariates or those with
multiple clusters in a linear model as fixed effects, a matrix of IC coefficients can
be generated by the get covariate mx() function. This will automatically
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select the IC coefficient values which show a significant association with a tested
covariate or estimated to have multiple clusters through detect clusters().
A custom matrix of selected ICs can also be easily retrieved in case the user
wishes to correct for IC effects that are not associated with covariates and also
not estimated to have multiple clusters. By incorporating these coefficients in
a linear model, the effects of factors that are not directly related to the variable
being tested can be corrected out to increase the statistical power of the analysis.
2.3.5 Visualization of Results
The results generated by ICA decomposition represent a high dimensional
structure, especially estimated components in S, thus effective visualization is
crucial in inspecting and analyzing the results. In picaplot, each IC is visual-
ized by combining the positional information of genes with their gene weights,
accompanied by the corresponding IC coefficients. To combine these results
for multiple components, we have implemented a report generating function
report gen(), which generates an HTML report containing gene weight plots
and IC coefficient plots with information regarding associated covariates and
key driver genes for every component.
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2.3.6 Application
To demonstrate the features of picaplotwe analyzed a publicly available gene
expression dataset described in [112]. We downloaded the dataset from the
Gene Expression Omnibus (GEO), using the accession number GSE60028. After
downloading the expression data and covariates, we first filtered the expres-
sion values to genes that are mapped to chromosomes 1 to 22, X and Y which
left us with 26419 genes measured for 47 samples. From the recorded covari-
ates, we selected gender, tested allergen, and the level of reaction to test the
association with estimated ICs. The example dataset that has been used is in-
cluded in the picaplot package and can be accessed by data(expr data,
sample info, probe info).
2.4 Results
42 independent components were estimated, based on the observation that 42
principal components explained more than 99 % of the total variance. We found
that the component estimated by ICA associated with the gender status of the
samples had the most significant covariate association p-value and it sepa-
rated the samples almost perfectly into two clusters, while the principal com-
ponent with the strongest association to gender showed a weaker separation
(Figure 2.4). The gene weight plots show that ICA identified fewer genes that
highly contribute to the component in comparison to PCA (357 versus 1198),
which could be explained a better separation of composite effects by ICA.
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Figure 2.4: Gender specific expression patterns estimated by ICA and PCA
picaplot visualizations of gene weight loadings showing highly contributing
genes in red and low contributors in grey ordered by their position in the
genome (top) and coefficient/projection visualization plots showing sample
clustering colored by the associated covariate (bottom). Components estimated
by ICA (left) and PCA (right) showing the components with the most
significant association with the known covariate gender.
We were able to replicate this finding by identifying components that were
highly associated with the gender status in a microarray dataset of smokers and
non-smokers, and an RNA-seq dataset obtained from the GTEx consortium. The
separation was clearer in microarray compared to RNA-seq, but in both cases
the separation was better than components estimated by PCA (Figure A.1). This
demonstrates that ICA can robustly estimate the gender specific effects from
gene expression profiles. These components could be used to estimate the gen-
der status if the covariate is missing, or as a quality control check to detect any
mis-labeled samples if the gender status was recorded.
We were also able to identify multiple components associated with allergens,
with the most significant associated component strongly separating the samples
between petrolatum and nickel as reported in the study. Additionally, ICA re-
turned multiple components showing no association with known covariates but
estimated to have multiple clusters (Figure 2.5).
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Figure 2.5: Allergen associated component and example of cluster estimation
Estimated IC associated with the allergen covariate is shown on the left. An
example of a component with multiple clusters detected by
detect cluster() with no known covariate association is shown on the
right.
2.5 Conclusion
Identifying and accounting for cryptic covariates when analyzing genome-wide
gene expression data is critically important for correct biological discovery.
Given that the cryptic covariates discovered by ICA are often expected to be
distinct from those returned by PCA, we highly recommend applying both
methodologies to any experiment. Not only can this information be used to
correctly account for hidden sources of variation, it can also be used to improve
the design of future experiments by understanding potential factors influenc-
ing gene expression levels. In summary, picaplot provides an easy-to-use, yet
comprehensive workflow to use both methods to inspect genome-wide gene ex-
pression data for cryptic covariates and to correct for and model these covariates
in subsequent analyses.
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CHAPTER 3
CONFETI: AN INDEPENDENT COMPONENT ANALYSIS
CONFOUNDING FACTOR CORRECTION FRAMEWORK
3.1 Introduction
Systematic variation introduced by non-genetic factors, such as technical vari-
ation caused by differences in laboratory procedures or distinct study envi-
ronments are major challenges in analyzing high dimensional gene expres-
sion measurements [8, 94, 113]. These can be especially problematic in de-
tecting small genetic effects in eQTL analysis, by obscuring true effects and
lowering the statistical power. To address this issue, multiple studies have
developed confounding factor correction methods based on various strate-
gies [66,76,77,88,89,91,114,115,116]. Generally, these confounding factor meth-
ods account for non-genetic variation in eQTL studies by learning and mod-
eling systematic variation directly from the multivariate structure observed in
gene expression data. When used in combination with corrections for popula-
tion structure [89], confounding factor analysis can both increase power in eQTL
studies and reduce false positives by accounting for non-genetic factors that im-
pact many genes. While confounding factor analyses should increase the correct
discovery of both cis- and trans-eQTL by increasing detection power [17, 113], a
known problem of all confounding factor methods is the potential to model
the effects of broad impact eQTL as confounding variation [77, 117]. Previous
approaches to avoid the removal of broad impact eQTL as confounding fac-
tors include, jointly estimating the error structure with genetic information [77],
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and using only a subset of genes to estimate the confounding structure [115].
However, such approaches do not explicitly identify individual confounding
factors and could generate different results based on selected genes, which is a
non-optimal strategy for avoiding the removal of variation produced by broad
impact eQTL.
In this chapter, we describe a new framework that is designed to improve
on the performance of confounding factor methods to identify broad impact
eQTL. The CONFETI (CONfounding Factor Estimation Through Independent
component analysis) framework makes use of ICA, described in the previous
chapter, to separate genetic components from non-genetic components learned
from multivariate gene expression variation. CONFETI takes advantages of the
key strength of ICA to estimate generative sources of variation from an observed
mixture, which can be used to separate independent sources of variation, such
as genetic versus non-genetic factors. After these generative sources have been
estimated by ICA, CONFETI automatically filters out those that are candidates
for broad impact eQTL variation and retains the rest as a lower dimensional rep-
resentation of the non-genetic confounding variation. By explicitly identifying
clear candidate signals of broad impact eQTL, CONFETI prevents the modeling
away of true genetic effects and increases the discovery potential of confound-
ing factor analyses.
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3.2 Design of the CONFETI Framework
The CONFETI framework is constructed to systematically avoid the tendency
of other confounding factor analysis methods to model broad impact eQTL as
confounding variation. This is accomplished by leveraging ICA to identify gen-
erative sources of multivariate gene expression variation and then screening
candidates based on component correlations with genotypes, which are then
omitted from the confounding factor correction (Fig 3.1). The reason ICA is par-
ticularly well suited for identifying candidate broad impact eQTL is that the
method is designed to separate independent sources of multivariate variation.
ICA assumes that the observed data for each sample is a linear combination
of non-Gaussian statistically independent components. When applying ICA,
the vector of expression values for an individual are modeled as weighted sum
of independent components:
~yi = ai1 ~s1 + ai2 ~s2 + · · · + aik ~sk =
k∑
j=1
ai js j (3.1)
where ~yi is a g-dimensional vector of gene expression values for a single sample,
and independent components ~s j are g-dimensional vectors of gene weights that
are shared among all samples and the scalar component coefficients ai j represent
the contribution of each independent component ~s j for sample i (Fig 3.1). When
considering all samples together, the above can be simply expressed as a matrix
decomposition:
Y = AS (3.2)
where Y is an n × g matrix with ith row ~yi. A is the n × k mixing matrix with
the jth column holding component coefficients ~a j for component j, and S is the
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Figure 3.1: The CONFETI framework
ICA is used to decompose the gene expression matrix Y into an IC coefficient
matrix A and a component matrix S. Associations between the genotypes and
coefficients in matrix A are tested to label any candidate genetic effects to be
removed from the correction. In the example above, the first IC, shown in red,
is marked as a candidate genetic component and the corresponding columns of
A and rows of S are removed. Using the lower rank A∗ and S∗, expression
values originating from non-genetic components are reconstructed in Y∗.
Finally, K is created by calculating the sample covariance matrix of Y∗, and
included as a random effect in the mixed model for eQTL analysis.
k × g independent component matrix in which the jth row is ~s j. A and S are
estimated by finding a projection of Y that maximizes the non-gaussianity of
the gene weight distribution of each row in S. In CONFETI these are identified
by using the FastICA algorithm for reliable and fast computation [108].
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Since ICA recovers factors by assessing non-gaussianity and not the amount
of variation explained as in methods such as Principal Component Analysis
(PCA) or any other factor analysis method [103], ICA is able to more clearly
resolve separate factors responsible for variation, while a PCA or factor anal-
ysis will tend to identify composite effects, which are likely to be mixtures of
multiple factors. The critical assumption for application of ICA in the CON-
FETI framework is that broad impact eQTL will have non-Gaussian impacts
on the multivariate expression profile and that the effects of these eQTL will
be relatively independent of other genetic and non-genetic factors. Complete
independence is not necessary, since the framework only has to identify and
retain enough of the expression variation due to a broad impact eQTL to make
it detectable with an association test. The assumption that broad impact eQTL
will tend to have non-Gaussian impacts is not particularly restrictive given that
we expect eQTL with large enough effects to impact only a subset of the to-
tal number of genes and therefore be detectably non-Gaussian. The assump-
tion that broad impact eQTL are relatively independent of each other is also
not overly restrictive in humans given the low linkage disequilibrium observed
among non-local genotypes throughout the genome. While the assumption that
broad impact eQTL are largely independent of non-genetic factors is not always
expected to hold, it seems likely in many cases unless there is a reason to expect
broad impact eQTL to strongly interact with non-genetic factors such as sample-
specific environmental effects or technical effects such as differences between
laboratories and procedures. Furthermore, in cases where broad impact eQTL
are completely conflated with non-genetic factors, these broad impact eQTL will
be indistinguishable from non-genetic contributions to the observed multivari-
ate gene expression variation and will be modeled away by any confounding
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factor method. In sum, the only accurately detectable broad impact eQTL are
those that have properties that are expected to make them identifiable by ICA.
The complete CONFETI framework involves running ICA on the multivari-
ate gene expression data, an automated detection step to identify candidate
broad impact eQTL by assessing associations with genotypes, and omission of
these factors for the construction of the random effect sample covariance ma-
trix used in a mixed model confounding factor analysis (Fig 3.1). While this
approach could be used in combination with confounding factor methods that
use a fixed covariate approach [88,90,91,116,118,119,120], the framework more
naturally integrates with mixed model approaches to confounding factor anal-
ysis, which do not suffer from the loss of power due to increased number of
parameters in the model. A covariance matrix constructed from the non-genetic
independent components is used to model confounding factors as random ef-
fects in a linear mixed model eQTL approach.
We note that our framework differs from ICA methods for eQTL detection
that treat the identified ICs as meta-genes, where these methods cannot reli-
ably distinguish the specific gene effects of individual eQTL [101,102]. The only
method that we are aware of close to this framework is ISVA, which uses ICA
within the Surrogate Variable Analysis (SVA) method for iteratively modeling
pre-specified fixed effects and confounding variation [90]. ISVA is not appropri-
ate for eQTL analysis since it begins the iterative approach by pre-specifying the
fixed effects and therefore pre-supposing the existence of a relationship, which
would introduce a bias towards finding eQTL false positives. CONFETI on
the other hand uses ICA to separate candidate broad impact eQTL without the
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need of pre-specifying the existence of the eQTL. We also note that in the mixed
model based method PANAMA [77], the authors discuss a strategy for avoid-
ing the over-correction of trans-eQTL by jointly estimating the covariance ma-
trix with genotype effects to avoid including those effects in the correction [77].
However, this approach is not a feature of PANAMA included in the LIMIX
package [121], which the authors have directed us to use. Moreover, the infor-
mation that can be obtained from the gene loadings are not considered in the
estimation step of PANAMA by being integrated out. In summary, the CON-
FETI framework utilizes the optimal properties of ICA to detect broad impact
eQTL by excluding genetic effects from confounding variation accounted for
in a mixed model, thereby taking advantage of the performance increases pro-
vided by mixed model confounding factor analysis without reducing the ability
to identify broad impact eQTL.
3.3 Methods
3.3.1 Independent Component Analysis
To apply ICA to gene expression data and generate a sample covariance ma-
trix, we developed a custom R package confeti which is publicly available
at https://github.com/jinhyunju/confeti. The independent compo-
nent estimation features are using functions adopted from the fastICA R pack-
age [122] which implemented the computationally efficient and robust FastICA
algorithm [108] based on a fixed-point algorithm to find directions maximiz-
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ing the negentropy to identify statistically independent components (ICs). The
number of ICs that can be estimated is the smaller of the sample size or the
number of features (genes), and the sign of any particular estimated component
is arbitrary. As the estimated ICs do not have any particular order and have
the potential to change based on the input of number of components to esti-
mate [90, 100, 123], the package supports diagnostics for assessing optimal IC
number such as functionality to estimate replicating ICs between multiple runs
for ensemble ICA estimation. In our analyses, we used the number of princi-
pal components that accounted for 95% of the data variance as the number of
components to be estimated to provide a fair comparison to PANAMA [77].
3.3.2 Removal of Candidate Broad Impact eQTL
After decomposing the observed data Y into A and S we test for any significant
associations between the component coefficients (columns of A) and all geno-
types. As in fixed effect eQTL models, we fit a linear regression model with the
IC coefficient as the dependent variable and the genotype values as indepen-
dent variables. After calculating p-values for each IC coefficient and genotype
pair we identified candidate broad impact eQTL using a Bonferroni corrected
p-value threshold of 0.05.
After filtering out r (0 ≤ r < k) components with significant genotype associ-
ation, we reconstruct expression matrix Y∗ originating from non-genetic factors
using the remaining k − r components:
Y∗ = A∗S∗ (3.3)
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where Y∗ is an n× g matrix, A∗ is a n× (k − r) matrix and S∗ is a (k − r)× g matrix.
3.3.3 Construction of the Sample Covariance Matrix
We used two approaches to construct the sample covariance matrix K for the
random effect part of the mixed model. Our first approach was to use a simple
location-scale normalization of each gene of Y∗:
Z∗ip = (Y
∗
ip − µp)/σp (3.4)
and then calculate sample covariance matrix:
K = cov(Z∗) (3.5)
We label this approach CONFETI-I since it can be thought of as a specific, lower
dimensional approach to Intersample Correlation Emended (ICE), one of the
first methods to estimate a sample structure for confounding factor analysis [66]
by estimating the sample covariance matrix using the full dimensional observed
expression data.
For our second approach, we couple CONFETI with PANAMA (Probabilistic
ANAlysis of genoMic dAta) [77] that estimates the covariance structure using a
maximum likelihood framework. Using this approach, the likelihood objective
can be stated as:
p(Y∗|Kpanama) =
g∏
p=1
N( ~y∗·p|τ2pKpanama + σ2pI) (3.6)
(θˆ, Cˆ) = argmaxθ,C p(Y
∗|C, θ) (3.7)
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where C is an n × Q matrix initialized by projecting the observed data onto the
first Q principal components explaining 95% of the variance, and θ is the set of
hyperparameters consisting of {{α2q}, σ2p}. Each α2q then represents the weight of
the qth column of C, C·q in constructing the sample covariance matrix:
K =
Q∑
q=1
αˆ2qCˆ·qCˆ
T
·q (3.8)
We label this approach CONFETI-P, where we use of the implementation of
PANAMA included in the LIMIX package [121] for the estimation of K.
3.3.4 Linear Mixed Model eQTL Analysis
We model the genetic effects from SNPs and covariates as fixed effects and con-
founding factor effects as random effects, such that the expression levels for
gene p in n individuals are:
~yp = X ~βp + ~cp + ~p (3.9)
~cp ∼ N(~0, τ2pK) (3.10)
~p ∼ N(~0, σ2pI) (3.11)
Where n is the number of samples, g the number of genes, s the number of SNPs,
and v the number of covariates. Each gene expression vector ~yp has dimension
n × 1 and is mean centered. The n × (s + v) genotype and covariate matrix X
indicates the number of minor alleles for each SNP coded as 0,1,2 and any addi-
tional covariates. ~βp is the (s + v) × 1 dimensional coefficient vector representing
the fixed effect of the SNPs and covariates on gene p. The confounding effect is
included in the model as a n × 1 random effect ~cp sampled from a multivariate
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normal distribution with covariance τ2pK, where K is the n × n sample covari-
ance matrix constructed the corresponding confounding correction method, τ2p
is a scalar weight for K in the random effect, and ~p is a n×1 vector representing
the independent error for gene p with scalar weight σ2p.
3.4 Conclusion
In this chapter, we have described our novel linear mixed model confounding
factor correction method CONFETI. The focus of CONFETI is to correctly dis-
tinguish genetic variation from non-genetic variation to maximize the potential
of broad impact eQTL discovery. In the following chapters, we compare the per-
formance of CONFETI with other linear mixed model based confounding factor
correction methods including PEER, ICE, and PANAMA. We first evaluate the
performance in simulated data where the ground truth is known to us.
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CHAPTER 4
COMPARISON OF CONFOUNDING FACTOR CORRECTION METHODS
USING SIMULATED DATA
4.1 Introduction
While the number of reported eQTL findings are increasing in various tissue
types across multiple human populations, only a very limited number of iden-
tified eQTL have been validated through experiments [124, 125]. Since a gold
standard dataset for known eQTL is not available, we first evaluated the perfor-
mance of multiple confounding factor correction methods using simulated data
in which the generative truth is known to us. We simulated eQTL data based
on yeast genotypes used in previous studies [126], in order to run multiple sim-
ulations with manageable data sizes. More specifically, we simulated cis, trans,
and broad impact eQTL, where cis and trans-eQTL are single gene-genotype
pairs, and broad impact eQTL are single genotypes associated with multiple
genes. By simulating these three eQTL categories, we investigated the balance
of each confounding factor correction method between correctly accounting for
non-genetic variance and retaining true genetic signals.
We compared CONFETI-I and CONFETI-P, described in the previous chap-
ter, to simple linear regression with no confounding factor correction (LINEAR),
a widely used confounding factor method probabilistic estimation of expression
residuals (PEER) [76], and mixed model confounding factor methods ICE [66]
and PANAMA [77]. Additionally, we also considered a strategy based on CON-
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FETI but substituting PCA for ICA, otherwise applying exactly the same ap-
proach to removal of principal components with significant genotype associa-
tions and calculating K for the remaining components weighted by the variance
they explain, an approach we labeled PCAKMX. We evaluate the performance
of each method by calculating the Area Under the Curve (AUC) for Receiver
Operating Characteristics (ROC) curves, and by investigating the True Positive
Rate (TPR) for varying False Discovery Rate (FDR) thresholds for the three cat-
egories of simulated eQTL.
4.2 Methods
4.2.1 eQTL Simulation
To mirror real cases where a reasonable number of broad impact eQTL have
been repeatedly identified, we used yeast as a model [72, 73, 74]. 2956 yeast
genotypes from the study of Smith et al. [126] and randomly sampled 3000
yeast gene annotations were used to create simulated datasets. The genome
coordinates of the genotypes and sampled genes were used to simulate cis and
trans-eQTL relationships. First, a matrix with a dimension of number of geno-
types × number of expression phenotypes was created that marked genotype
and phenotype pairs cis if the starting position of the gene and the genotype
were within 100,000 bases and trans if the distance was greater. From this ma-
trix we sampled 2500 genotype and phenotype pairs which consisted of 80% cis
and 20% trans relationships. In total, for each simulated dataset, we included
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2000 cis-eQTL, 500 trans-eQTL, and 10 broad impact eQTL. We simulated each
broad impact eQTL to affect 10% of the expression phenotypes. Effect sizes for
cis-eQTL were sampled fromN(0.8, 1) and effect sizes for trans-eQTL and broad
impact eQTL were sampled from N(0.48, 1) (70% attenuation of trans-effects) to
reflect observed effect sizes in real data. After the eQTL effects were simulated,
we added normally distributed random noise sampled from N(0, 1). For con-
founding factor effects, we simulated two types of confounding factors: sparse
and dense. For sparse confounding factors 30% of phenotypes were affected
with effect sizes drawn from N(1, 0.5), and for the dense confounding factors,
the effect over all genes followed a standard normal distribution N(0, 1). We
tested 2 scenarios, each with 30 confounding factors: sparse only, and mixed (15
sparse and 15 dense). We simulated and analyzed 50 datasets for each of these
two scenarios, a total of 100 datasets.
4.2.2 Confounding Factor Correction Methods
We compared CONFETI-I and CONFETI-P, as described in the previous chapter,
to other published confounding factor correction methods PEER, PANAMA,
and ICE. Here, we briefly review the confounding factor correction methods.
PEER As a bayesian factor analysis model, PEER estimates Gaussian factors
from a given expression matrix and uses automatic relevance detection (ARD)
to discard factors of minimal importance [76].
P(Yip|fi,wp, τp) = N(Yip|
K∑
k=1
wp,k fk,i,
1
τp
) (4.1)
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P(wp,k|βk) = N(wp,k|0, 1
βk
) (4.2)
P( fk,i) = N( fk,i|0, 1) (4.3)
As shown in the above equation, each gene expression level for individual i and
gene p, Yip, is modeled as a linear combination of k Gaussian factors wp and
their associated gaussian weights fi, with gamma priors on noise precisions τp
and βk. Estimated factor weights can be included in the model as fixed effects
or a residual matrix can be calculated by subtracting the factor effects from the
phenotype matrix. Here, we chose to include the estimated factor weights as
covariates in the linear fixed effect model and used 25% of the sample size as
the initial number of factors as recommended by the authors [120].
ICE In the ICE framework [66], the sample correlation structure is used to ap-
proximate the confounding factor effects. First, the expression values are mean
centered and divided by the standard deviation, and the sample covariance ma-
trix is calculated by the covariance of the normalized expression values. This
is analogous to substituting the lower dimensional Y∗ with the full expression
value matrix Y in equations 3.4 and 3.5.
PANAMA A maximum likelihood approach is used to estimate factors that
best explain the phenotype covariance structure in PANAMA [77]. Similar to
ICE, considering the full expression matrix Y instead of Y∗ in equations 3.6, 3.7,
and 3.8 outlines the process of PANAMA.
45
PCAKMX In this approach, we substitute ICA with PCA in estimating a lower
dimensional representation. Running PCA will result in n orthogonal compo-
nents of g dimensions P, and the relative amount of the total variance each com-
ponent explains. These components can project the measured expression levels
Y onto a lower dimensional space T.
YPT = T (4.4)
These projections are then tested for associations with genotype values to re-
move candidate genetic effects, analogous to the process of CONFETI. Then the
projections are weighted by the percent variance they explain and a sample co-
variance matrix is calculated by taking the covariance matrix of the weighted
projections.
For PEER we used the glmApply() function in the R package lrgpr to fit
a linear fixed effect model for each phenotype and genotype combination with
PEER weights included as covariates. Linear mixed models for CONFETI-I,
CONFETI-P, PANAMA, PCAKMX, and ICE were fit using the lrgpr() func-
tion from the same package.
4.2.3 Genomic Inflation Factor to Assess Model Fit
To assess model fit and to avoid any systematic inflation or deflation of the p-
values, we calculated the genomic inflation factor λ statistic for each expression
phenotype. The λ statistic was calculated per gene using the median p-value mp
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as
λp = qchisq(1 − mp)/qchisq(0.5) (4.5)
where qchisq is a quantile function for the chi-square distribution with 1 degree
of freedom. For each method we assessed inflation using λp values for every
gene to calculate λdiff,p = 1 − λp.
4.2.4 Performance Evalulation
To evaluate performance for each method, we ranked the eQTL for each method
according to their p-values and then calculated the True Positive Rate (TPR)
and False Positive Rate (FPR) and generated Receiver Operating Characteris-
tic (ROC) curves for each method, where we also calculated the area under the
curve for each method across the simulation scenarios. True eQTL were further
labeled as cis, trans or broad impact and the recovery rates for each category at
different FDR thresholds were calculated by dividing the number of true geno-
type phenotype pairs that were called significant by the total number of true
genotype phenotype pairs in each category. To provide an upper bound metric
on how well methods could recover each of these eQTL types, we also simu-
lated the same scenarios without any confounding factors and reported the ROC
curves after running LINEAR. We labeled these results ‘TMR’ for ‘Theoretical
Maximum Recovery’ since these represent the maximum recovery expected in
theory if non-genetic factors were perfectly modeled by the confounding factor
methods.
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4.3 Results
In our analysis of simulated data, we assessed the performance of the eQTL
analysis methods CONFETI-I, CONFETI-P, PANAMA, PCAKMX, ICE, PEER,
and LINEAR on their ability to identify three types of eQTL, cis, trans and broad
impact, in the presence of confounding factors. We also included the theoret-
ical maximum recovery (TMR) as an upper limit of eQTL detection for each
eQTL category, where the phenotype data has only normally distributed ran-
dom noise added without any confounding factor effects.
4.3.1 Model Fit
First, we evaluated the model fit by calculating genomic inflation factors for
each method to detect any significant inflation or deflation of p-values. In
the presence of sparse confounding factor effects, CONFETI-I, CONFETI-P,
PCAKMX, PEER, and LINEAR showed a moderate level of p-value inflation
(Figure 4.1), while PANAMA and ICE showed slightly more conservative model
fits compared to other methods. The same trend was observed in the pres-
ence of mixed confounding factor effects, with the only difference being that
PCAKMX had a slightly less inflated model fit in the latter case. Interestingly,
TMR showed a moderate inflation of p-values as well without any confound-
ing factor effects present. This led to the conclusion that the inflation of p-
values were likely caused by the large LD blocks observed in the yeast genome,
which result in lower p-values in many genotypes due to their correlation with
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the causal variant. The more conservative fit observed in PCAKMX, ICE, and
PANAMA in comparison to TMR, could be explained by the methods incor-
rectly explaining away genetic effects as confounding variance.
Figure 4.1: Model fit assessment for simulated data
Box-plots of genomic inflation factors calculated for each method across the 50
simulated datasets with A. sparse and B. mix of sparse and dense confounding
factors.
4.3.2 Overall Method Performance Comparison
For both sparse and dense confounding factor effects, all confounding factor
correction methods showed a significant increase in the AUC of ROC curves
over LINEAR (linear regression without confounding factor correction). Out of
the compared confounding factor correction methods, CONFETI-I, closely fol-
lowed by CONFETI-P, showed the largest improvement over LINEAR in both
scenarios of sparse and mixed confounding factors. PANAMA, ICE and PEER
showed similar degrees of improvement. Interestingly, PCAKMX showed the
lowest degree of improvement in both scenarios. We first hypothesized that
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this occurred due to the incorrect removal of components associated with tested
genotypes, since PCA was likely to estimated composite effects. However, upon
closer inspection we found that both the number of removed principal com-
ponents and their corresponding contribution to the overall variance were not
significant, thus we concluded that constructing the covariance matrix based on
PC projections weighted by the percent variance they explain was a sub-optimal
strategy.
Figure 4.2: Area Under Curve (AUC) calculated for ROC curves
The Area Under the Curve (AUC) for the receiver operator characteristic
(ROC) curves for simulated data with A. sparse confounding factors and B.
mix of sparse and dense confounding factors.
4.3.3 True Positive Rate by Simulated eQTL Categories
To further investigate the accuracy in recovering simulated eQTL, we compared
the true positive rate (TPR) of each eQTL category (cis, trans, and broad impact)
at varying FDR thresholds. CONFETI-I and CONFETI-P correctly identified the
most eQTL in all three categories in the presence of sparse confounding factors
(Figure 4.3A). For broad impact eQTL in particular, CONFETI-I and CONFETI-
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P outperformed all other methods by a large margin. PEER and PCAKMX
also performed relatively well in estimating broad impact eQTL over ICE and
PANAMA, but fell short in identifying individual cis- and trans- eQTL. The dif-
ference in broad impact eQTL recovery seemed to largely stem from the dis-
tinction between genetic and non-genetic effects, since methods that removed
genetic effects from the sample covariance matrix (CONFETI-I, CONFETI-P,
PCAKMX) seemed to generally perform better than the methods which made
no such distinction (PANAMA, ICE). This did not affect the performance of
PEER in broad impact eQTL discovery at such extend, since PEER estimates
a fixed number of gaussian confounding factors which likely would have not
led to an accurate estimate of the broad impact eQTL effects.
The difference between the confounding factor methods decreased with a
combination of sparse and dense confounding factors compared to cases with
just sparse confounding factors (Figure 4.3B), especially in the identification of
broad impact eQTL. This is likely due to the difference between the relative
amount of total variance explained by each confounding factor and broad im-
pact eQTL. In the dense confounding factor scenario, the confounding factors
contribute a significantly higher proportion of the total variance compared to
broad impact eQTL. In such a case, distinguishing genetic variance from non-
genetic variance has less influence on the covariance matrix estimation, since
the majority of the variation in the data is originating from the confounding fac-
tors, and the resulting difference between methods in identifying true eQTL is
expected to be smaller. Overall, CONFETI-I still identified eQTL in all three
categories most accurately, but interestingly CONFETI-P fell below ICE and
PANAMA in cis and trans-eQTL recovery.
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Figure 4.3: True Positive Rate calculated for each simulated eQTL category
The recovery rate of simulated cis- (left), trans- (middle) and broad impact
eQTL (right) for a range of FDR significance thresholds for each method
averaging over the 50 simulated datasets with a A. sparse and B. a mix of
dense and sparse confounding factors. The theoretical maximum recovery
(TMR) shows the recovery when no confounding factors are included.
4.4 Conclusion
In summary, we demonstrated that linear mixed models that correctly modeled
the sample structure with their covariance matrices more accurately detected cis
and trans-eQTL compared to other methods. However, approaches such as ICE
and PANAMA, which do not explicitly remove genetic effects from their covari-
ance matrix construction, incorrectly modeled broad impact eQTL as confound-
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ing factors. While the extent to which any simulated data will capture the true
confounding factor conditions and genetic architectures of real eQTL datasets
is unknown, these simulations demonstrate that the CONFETI framework can
provide a considerable performance improvement compared to mixed model
confounding factor methods in some situations, and performed at least as well
as other methods overall.
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CHAPTER 5
EVALUATING THE PERFORMANCE OF CONFOUNDING FACTOR
CORRECTION METHODS THROUGH REPLICATING EQTL IN HUMAN
DATA
While an increasing number of eQTL results are published every year, hu-
man eQTL studies lack a standardized methodology and often have different
platforms for genotyping and expression measurements. Since the direct com-
parison of results between studies is difficult, the validity of an identified eQTL
is not known for most cases. Therefore, without experimental validation evalu-
ating the quality of eQTL findings is challenging in human datasets. To evaluate
the performance of CONFETI compared to other confounding factor correction
methods, we re-analyzed multiple human datasets using a central pipeline and
inspected the replication of eQTL findings between datasets. We note that this is
an imperfect metric that will tend to undercount true positives, however, repli-
cation does provide relative control over non-systematic false positives, such
that a method that is overly liberal in calling eQTL false positives will be appro-
priately assessed.
The ideal way to assess the replication of eQTL would be to use exact bi-
ological replicates, however, since such datasets are not readily available we
first analyzed datasets from the Multiple Tissue Human Expression Resource
(MuTHER), which consisted of a cohort of 856 monozygotic and dizygotic twins
from the TwinsUK adult registry [18]. We split the dataset by twin pairs to
closely mimic biological replicates resulting in subsets with highly similar ge-
netic variation structures. In summary, we analyzed a total of 6 subsets derived
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from adipose, lymphoblastoid cell lines (LCL), and skin datasets.
To investigate and compare the analysis results of the MuTHER dataset,
we expanded our scope to additional tissue types by analyzing data from the
Genotype-Tissue Expression (GTEx) consortium [22]. GTEx datasets did not
have the same twin design as MuTHER, but multiple tissue samples were taken
from a single individual resulting in similar genetic structures across tissues.
We selected 4 pairs of samples that originated from similar tissue types with
comparable sample sizes to assess the replication of eQTL.
We first evaluated the model fit by calculating the genomic inflation fac-
tor statistic for each phenotype in every dataset. Secondly, we investigated
the number of identified cis and trans-eQTL in each individual dataset in both
MuTHER and GTEx. We then compared the eQTL findings between twin pairs
in the MuTHER analysis, and between similar tissue types in the GTEx analysis.
Finally, we inspected replicating cis and trans-eQTL across all datasets for both
MuTHER and GTEx.
5.1 Methods
5.1.1 Analysis of MuTHER Datasets
We ran eQTL analysis on the adipose, LCL, and skin datasets obtained through
the MuTHER project. Based on the matched twins information, there were 161
monozygotic and 220 dizygotic twin pairs in the dataset. We only selected sam-
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ples that had both genotype and gene expression measurements for both in-
dividuals in each twin pair for all three tissue types. Then we split each tissue
specific dataset into two subsets separating each twin pair into different subsets.
This created two subsets for each tissue type resulting with 327 samples for adi-
pose, 329 for LCL, and 253 samples for skin. From the downloaded genotypes,
we used only non-imputed genotypes with minor allele frequencies higher than
0.05.
Table 5.1: Sample size, number of genes and genotypes for each MuTHER
dataset analyzed.
Tissue Sample Size Gene Expression Genotypes
Adipose 327 28964 246298
LCL 329 28894 246298
Skin 253 28893 246298
5.1.2 Analysis of GTEx Datasets
We selected 4 pairs of tissues (Adipose, Artery, Heart, Skin) from GTEx release
v6 (dbGaP Accession phs000424.v6.p1) with over 150 samples that have both
RNA-seq gene expression and SNP array genotypes (Table 5.2). For gene ex-
pression measurements, we used the pre-processed expression values directly
obtained from the GTEx portal. For genotypes, we excluded SNPs with missing
genotypes and those with minor allele frequency < 0.05. We also pruned SNPs
within 10kb with pairwise r2 > 0.99 and removed SNPs which were deprecated
in dbSNP (1,270,565 SNPs remaining).
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Table 5.2: Sample size, number of genes and genotypes for each GTEx dataset
analyzed.
Tissue Subtype Sample Size Gene Expression Genotypes
Adipose Subcutaneous 298 27182 1270565
Adipose Visceral 185 26261 1270565
Artery Aorta 197 25292 1270565
Artery Tibial 285 25311 1270565
Heart Atrial Appendage 159 24541 1270565
Heart Left Ventricle 190 23710 1270565
Skin Leg 302 27815 1270565
Skin Suprapubic 196 26913 1270565
5.1.3 eQTL Analysis
We fit CONFETI-I, CONFETI-P, PANAMA, PCAKMX, ICE, PEER, and LINEAR
for every phenotype and genotype pair using the method settings and param-
eters as described in the previous chapter. We used genotype principal compo-
nents included as covariates (2 for each MuTHER and 3 for GTEx datasets) to
account for population structure. Additionally, we used age and experimental
batch as covariates for the MuTHER analysis, and used gender and genotyp-
ing platform as covariates for the GTEx analysis. After calculating p-values for
all phenotype and genotype pairs, we adjusted the p-values using Benjamini-
Hochberg multiple hypothesis correction. The corrected p-values represent up-
per bounds on False Discovery Rate (FDR) [127]. We used a threshold of 0.01
on the adjusted p-values to mark significant eQTL. An eQTL (significant SNP
gene pair) was labeled as cis if the SNP and gene were located on the same
chromosome within 1 Mb, and trans otherwise. We screened all trans-eQTL for
cases where the SNP was coincident either with an annotated gene copy (such
as a pseudogene or functional gene ‘parent’ of a pseudogene), or a region of
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the genome with high sequence similarity (covering at least 30% of the gene
transcript) to the eQTL gene. These unannotated regions were identified by
aligning all gene transcripts to the entire genome using the BLAT tool [128].
This “pseudo-trans” screening revealed that a number of the replicating trans-
eQTL were artifacts arising due to incorrect/ambiguous mapping of RNA-seq
reads that are in fact caused by cis-regulation of a gene which shares sequence
similarity with the eQTL gene. In order to avoid double-counting eQTL asso-
ciated with multiple linked SNPs, we selected at most one significant cis- and
trans- SNP per cytoband per gene. Using these criteria, we measured the repli-
cation of eQTL between and across different tissues counting the overlapping
cytoband and gene pairs that were called significant in each dataset.
5.2 Results
5.2.1 Model fit
We ran each of the eQTL analysis methods on six MuTHER [18] datasets con-
sisting of three twin pairs for adipose, LCL and skin samples and the eight
GTEx [22] datasets made up of four tissue pairs (Adipose, Visceral vs. Sub-
cutaneous; Artery, Aorta vs Tibial Artery; Heart, Atrial Appendage vs. Left
Ventricle; Skin, Leg vs. Suprapubic). For each method applied to each dataset,
we inspected the median λ genomic inflation factor [79] as a measure of appro-
priate model fit and control of false positives and false negatives rates.
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MuTHER All methods were within acceptable fit levels with no significant in-
flation or deflation with genotype PCs included as covariates (Figure 5.1A). One
interesting observation was that ICE consistently showed a slightly higher mea-
sure of inflation factors in all datasets compared to other methods. This was not
observed in the analysis of simulated data, where CONFETI-I and CONFETI-P
showed a slight inflation. This could be caused by an increased number of false
positives, or it could illustrate that ICE corrects the confounding factor effects
best and is able to recover the highest number of eQTL results. However, with-
out the validation of results returned by all methods, the exact cause remains
unknown. Additionally, an overall trend of linear fixed effect models showing
a slightly more conservative fit than linear mixed model based approaches was
observed in all datasets (Figure 5.1A and Figure B.1A).
GTEx Similar to the model fit evaluation of MuTHER datasets, we observed
a slight inflation of p-values in ICE results (Figure 5.1B, Figure B.1B). Linear
fixed effect models also tended to be more conservative than linear mixed mod-
els in the GTEx data, and the largest difference between methods was observed
in the GTEx heart atrial appendage dataset (Figure 5.1B). The heart atrial ap-
pendage dataset showed also the highest degree of inflation in all of the lin-
ear mixed model approaches. Interestingly, this dataset had the smallest sam-
ple size, which could have resulted in a less accurate estimation of the sample
structure by confounding factor methods (Table 5.2). This observation is also
repeated in the skin subsets of MuTHER (Figure 5.1A, Figure B.1A) with the
smallest sample size out of the three tissues (Table 5.1).
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Figure 5.1: MuTHER and GTEx model fit evaluation
Genomic inflation factors calculated for each analysis method in each
sub-dataset of A. MuTHER and B. GTEx.
5.2.2 eQTL Discovery in Individual Datasets
MuTHER The number of both cis and trans-eQTL discoveries increased for
less stringent FDR thresholds in all of the datasets (Figure B.3). A significant dif-
ference between cis and trans-eQTL was that while the number of trans-eQTL in-
creased steadily with a linear relationship to the significant threshold, the count
of cis-eQTL seemed to increase at a much lower rate and most cis-eQTL were
identified even with the most stringent threshold. This could be explained by
the generally lower effect sizes of trans-eQTL, but could also be caused by an
increase of false positive discoveries as the threshold is lowered.
Confounding factor methods greatly increased the number of identified cis-
eQTL in all datasets by approximately 2-3 fold compared to LINEAR, demon-
strating the increase of power by accounting for systematic variation. Little dif-
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ference was found in the number of identified cis-eQTL between linear mixed
model confounding factor methods, except for PCAKMX which found notably
fewer cis-eQTL in all datasets compared to CONFETI-I, CONFETI-P, PANAMA
and ICE. In agreement with the simulation results (Figure 4.2), PEER identified
more cis-eQTL in both the adipose and LCL dataset compared to PCAKMX and
a comparable number of cis-eQTL in the skin dataset, illustrating that confound-
ing factor estimation through PEER is a better strategy for cis-eQTL discovery
in comparison to PCAKMX.
Considering an FDR threshold of 0.01, fewer trans-eQTL were identified
compared to the number of cis-eQTL in all datasets and all methods. ICE found
the most trans-eQTL in all cases except the second subset of the skin dataset, and
similar to cis-eQTL the observed difference between linear mixed model based
approaches was minimal. The difference in trans-eQTL discovery in the second
subset of the skin dataset seems to be driven from the removal of components
associated with genotypes, since only the methods which removed candidate
genetic effects (CONFETI-I, CONFETI-P, and PCAKMX) show an increase in
trans-eQTL identification in comparison to the first subset. Another interesting
observation was that out of the confounding factor correction methods, only
PEER recovered fewer trans-eQTL in comparison to LINEAR, in one subset of
adipose and in both skin subsets compared to LINEAR. This could be poten-
tially explained by the lower statistical power of PEER in detecting weaker ef-
fects due to the increased number of parameters, but could also depict the po-
tential over correction of real effects by PEER.
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GTEx Results obtained by analyzing tissue pairs from the GTEx dataset pre-
sented similar findings to the MuTHER dataset. cis-eQTL discovery started to
asymptote while the number of identified trans-eQTL steadily increased in all
datasets and all analysis methods (Figure B.4). The absolute number of identi-
fied eQTL differed between datasets showing a positive correlation with larger
sample size (Figure B.2).
Consistent with the findings in the MuTHER dataset, confounding factor
methods greatly increased the number of identified cis-eQTL compared to LIN-
EAR with the largest increases observed with linear mixed model based meth-
ods ICE, CONFETI-I, CONFETI-P, and PANAMA. Out of the linear mixed
model based methods, ICE constantly identified the most cis-eQTL across all
datasets. PEER also found more cis-eQTL in comparison to PCAKMX in all
datasets except the heart artial appendage dataset, reinforcing the finding in
MuTHER that given a sufficient sample size PEER outperforms PCAKMX in
cis-eQTL discovery.
ICE identified the most trans-eQTL in all analyzed datasets, followed by
CONFETI-I, CONFETI-P and PANAMA, which showed minimal difference in
the number of identified trans-eQTL. Unlike cis-eQTL PEER constantly found
fewer trans-eQTL compared to PCAKMX, but identified more hits compared to
LINEAR.
In summary, correction for confounding factor effects increased the num-
ber of identified cis-eQTL in all datasets when compared to the linear model
with only known covariates included. The greatest increase in identified hits
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was observed when a linear mixed model which accounted for most of the ob-
served variance was used (CONFETI-I, CONFETI-P, ICE, and PANAMA). Simi-
lar trends were observed in trans-eQTL discovery as well, with a few exceptions
of PEER finding fewer trans-eQTL in comparison to LINEAR in the analysis of
MuTHER datasets.
5.2.3 Replicating eQTL Compared Across Methods
To further investigate the results generated by all methods in both MuTHER
and GTEx datasets, we first assessed the replication of each identified eQTL
between each twin pair in MuTHER and in each tissue pair dataset in GTEx.
MuTHER First, in Figure 5.2A we show the replication of cis-eQTL in the adi-
pose twin-pair datasets. The identification of replicating cis-eQTL at different
FDR thresholds resembled the discovery of cis-eQTL in each individual dataset.
With most of the replicating cis-eQTL being identified at very stringent signifi-
cance thresholds, the number of replicating cis-eQTL increased at a low rate for
less stringent thresholds. For an FDR threshold of < 0.01, the replicating cis-
eQTL were largely overlapping between CONFETI-I, CONFETI-P, PANAMA
and ICE, while only a few unique results were found by each method. Addition-
ally, replicating cis-eQTL identified by PCAKMX, PEER and LINEAR were sub-
sets of hits identified by other methods, showing that CONFETI-I, CONFETI-P,
PANAMA, and ICE were identifying eQTL additional to the results of LINEAR,
PEER, and PCAKMX. The same trend was observed in the analysis of LCL (Fig-
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ure B.5A) and in skin (Figure B.6A) datasets. For each analysis method in each
MuTHER subset pair, the percentage of replicating cis-eQTL were between 60%
to 80% of cis-eQTL (Figure 5.3A).
Figure 5.2: Replicating eQTL in the MuTHER Adipose Subsets
Plots showing replicating eQTL for A.cis and B.trans-eQTL at an FDR threshold
of 0.01 across all methods (left) and the count of replicating eQTL versus
various FDR thresholds for each of the analysis methods (right). In the plots on
left, replicating eQTL are ordered on the x-axis by the amount of overlap
between methods. Colored bars corresponding to their method indicate that
the particular eQTL replicated, and the total number of replicating eQTL for
each method is shown at the end of each bar.
In contrary to cis-eQTL, we found that a only a very small number of trans-
eQTL replicated within the adipose twin pair dataset (Figure 5.2B). The num-
ber of replicating trans-eQTL only accounted for less than 10% of the union of
unique trans-eQTL identified in each dataset with the exception of PEER and
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LINEAR in the LCL analysis (Figure 5.3B). This trend could be explained by the
comparably lower number of trans-eQTL that LINEAR and PEER identified,
which led to a higher replicating fraction driven by a few replicating eQTL.
Moreover, if a few cis-eQTL were mis-classified as trans-eQTL due to having
a distance slightly larger than the threshold of 1Mb or due to mis-mapping of
the gene, LINEAR and PEER would likely only identify these as trans-eQTL
thus having a higher replication rate. Another observed trend was that unlike
the sharply increasing trans-eQTL findings in each dataset, the number of repli-
cating trans-eQTL only showed a slight increase as the significance threshold
was lowered. The analysis results of LCL (Figure B.5B) and skin (Figure B.6B)
datasets showed similar findings, with LCL having the most replicating trans-
eQTL. Based on these results, we concluded that the low replication rate of
trans-eQTL cannot be solely attributed to lower effect size, which raised con-
cerns about their credibility as biological findings.
GTEx To present a direct comparison with the MuTHER analysis, in Fig-
ure 5.4A we first present the results for replicating cis-eQTL identified in the
GTEx adipose tissue pair. We found a large number of replicating cis-eQTL
between the GTEx adipose subcutaneous and visceral datasets, and the major-
ity of replicating cis-eQTL were identified at stringent thresholds. CONFETI-I,
CONFETI-P, PANAMA, and ICE found similar numbers of replicating cis-eQTL
with ICE having the most unique replicating eQTL. Interestingly, the number
of replicating cis-eQTL found by PEER and PCAKMX were comparable, de-
spite the fact that PEER identified more cis-eQTL hits in each dataset separately.
Ranging between 35% to 45% the percentage of replicating cis-eQTL was lower
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Figure 5.3: Fraction of replicating eQTL in the MuTHER and GTEx datasets
A. Fraction of replicating cis-eQTL and B. trans-eQTL are calculated by
dividing the number of replicating eQTL by the union of unique eQTL found
in each dataset pair.
compared to the MuTHER analysis (Figure 5.3A). This could be due to the dif-
ference between the tissue subtypes which was a heterogeneity not present in
the MuTHER dataset. Another explanation could be the difference in sample
size between subcutaneous (298) and visceral (185) subsets, leading to more cis-
eQTL overall which are primarily identified in the subcutaneous dataset. How-
ever, given the higher replication ratio in the artery dataset, which has a similar
sample size difference to the adipose subsets (Aorta 197 vs Tibial 285), the dif-
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ference between the tissue types would be a more likely explanation.
Figure 5.4: Replicating eQTL between GTEx Adipose Subcutaneous and Vis-
ceral
Plots showing replicating eQTL for A.cis and B.trans-eQTL at an FDR threshold
of 0.01 across all methods (left) and the count of replicating eQTL versus
various FDR thresholds for each of the analysis methods (right). In the plots on
left, replicating eQTL are ordered on the x-axis by the amount of overlap
between methods. Colored bars corresponding to their method indicate that
the particular eQTL replicated, and the total number of replicating eQTL for
each method is shown at the end of each bar.
A higher number of replicating trans-eQTL were identified in the GTEx adi-
pose analysis compared to the MuTHER adipose results (Figure 5.4B), how-
ever, trans-eQTL still showed poor replication rates when considering the over-
all number of identified trans-eQTL in each dataset (Figure 5.3B). trans-eQTL
identified by LINEAR and PEER showed a much higher replication ratio com-
pared to other methods, which could be explained by similar reasons mentioned
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in the MuTHER replication analysis. The replicating cis and trans-eQTL results
of artery (Figure B.7), heart (Figure B.8), and skin (Figure B.9) datasets showed
consistent trends in comparison to the adipose dataset results.
In summary, we demonstrated that in both matched twin-pair and tissue-
pair analysis of multiple tissues that cis-eQTL findings were highly replicable,
whereas trans-eQTL showed a much lower replication rate. Results between
linear mixed model methods CONFETI-I, CONFETI-P, PANAMA, and ICE
showed only small differences identifying largely the same replicating eQTL
for both cis and trans. These methods also found almost all eQTL identified by
PCAKMX, PEER, and LINEAR indicating a higher statistical power for meth-
ods with estimated sample covariance matrices that account for confounding
variance.
5.2.4 Replication of cis and trans eQTL across datasets
MuTHER Comparing cis-eQTL and trans-eQTL that were identified across
datasets revealed another striking difference between the two categories. cis-
eQTL showed a high rate of replication between all datasets, with more than
70% of the total cis-eQTL being replicated in more than one dataset for all anal-
ysis methods (Figure 5.5). Interestingly, the fraction of replicating cis-eQTL were
broadly similar across all analysis methods. A high fraction of cis-eQTL repli-
cated in 2 subsets, which demonstrated the difference in gene regulation be-
tween the adipose, LCL, skin tissues. These could be seen as replicating cis-
eQTL blocks specific to each tissue type in Figure 5.6A. Out of the three tissue
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types, LCL subsets showed the largest amount of replicating tissue specific cis-
eQTL (Figure 5.6A).
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Figure 5.5: Fraction of replicating eQTL by number of MuTHER datasets iden-
tified in
Bar plots showing the fraction of total cis and trans-eQTL by the number of
datasets they were found in for the MuTHER analysis.
The replicating fraction of eQTL were also consistent between analysis meth-
ods for trans-eQTL. However, in contrast to cis-eQTL, more than 90% of the
trans-eQTL were only identified in a single subset showing minimal overlap
even between the same tissue types (Figure 5.5). Given the twin pair design of
the analysis, we expected to see an enrichment of replicating trans-eQTL found
in 2 datasets similar to cis-eQTL, however the evidence for such a trend was
minimal. We observed replicating trans-eQTL that were specific to the LCL sub-
sets, however, compared to tissue specific cis-eQTL the fraction of such replicat-
ing trans-eQTL fell short by a large margin (Figure 5.6B).
The comparison of replicating eQTL identified by each method across all
datasets yielded similar results to the replication results in twin pairs for each
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Figure 5.6: cis-eQTL and trans-eQTL overlap across datasets in the MuTHER
analysis
Unique A. cis-eQTL and B. trans-eQTL found in each dataset by CONFETI-I
are ordered on the x-axis by the amount of overlap between different datasets.
Colored bars corresponding to their tissue types (Adipose, LCL, Skin) indicate
that the particular eQTL was identified in the dataset, and white space
indicates that the eQTL was not found. The total number of replicating eQTL
are shown on the right. The black scale on the bottom right of each plot shows
the length covering 500 eQTL.
tissue type. ICE found the highest number of cis-eQTL replicating across all
datasets (756), closely followed by PANAMA (737), CONFETI-I (714), and
CONFETI-P (689) at an FDR threshold of 0.01 (Figure 5.7). For trans-eQTL, ICE
and PANAMA found the same 5 replicating hits across datasets, while others
found fewer. Upon closer inspection only 1 trans-eQTL out of the 5 had a geno-
type and gene that were on different chromosomes, while the other 4 were likely
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driven by cis-eQTL that were slightly outside of the 1Mb window (Figure B.10).
Figure 5.7: Replicating eQTL across all MuTHER datasets
Plots showing replicating eQTL for A.cis and B.trans-eQTL at an FDR threshold
of 0.01 across all methods (left) and the count of replicating eQTL versus
various FDR thresholds for each of the analysis methods (right). In the plots on
left, replicating eQTL are ordered on the x-axis by the amount of overlap
between methods. Colored bars corresponding to their method indicate that
the particular eQTL replicated, and the total number of replicating eQTL for
each method is shown at the end of each bar.
GTEx When we investigated replicating eQTL across all GTEx datasets we
found that while more than 60% of the cis-eQTL replicated in more than one
dataset, the fraction of cis-eQTL that replicated between 2 datasets significantly
reduced compared to the MuTHER analysis (Figure 5.8). This stems likely from
the difference between tissue subsets, since tissue samples obtained from differ-
ent locations of the body are expected to be less similar than subsets of samples
from the same tissue type. Moreover, the cell type composition of the sam-
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pled region might also differ, which can be a source of additional heterogeneity.
However, we were still able to find tissue type specific cis-eQTL in the GTEx
analysis, where the overlap between the skin and artery subsets produced the
most tissue specific cis-eQTL (Figure 5.9).
cis trans
0.00
0.25
0.50
0.75
1.00
1 2 3 4 5 6 7 8 1 2 3 4 5 6 7 8
Number of Datasets
Fr
ac
tio
n 
of
 T
o
ta
l e
QT
L
method
CONFETI−I
CONFETI−P
PANAMA
PCAKMX
ICE
PEER
LINEAR
Figure 5.8: Fraction of replicating eQTL by number of GTEx datasets identified
in
Bar plots showing the fraction of total cis and trans-eQTL by the number of
datasets they were found in for the GTEx analysis.
The findings in trans-eQTL replication across all datasets were consistent
with those in the MuTHER analysis, where more than 90% of the identified
trans-eQTL by all methods except LINEAR were specific to the dataset and
showed poor replication overall. LINEAR showed a slightly higher fraction
of trans-eQTL that replicated in more than one dataset, however this is likely
due to the significantly smaller number of trans-eQTL identified by LINEAR in
comparison to other methods.
At an FDR threshold of 0.01, ICE found the most cis-eQTL replicating across
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Figure 5.9: cis-eQTL and trans-eQTL overlap across datasets in the GTEx analy-
sis
Unique A. cis-eQTL and B. trans-eQTL found in each dataset by CONFETI-I
are ordered on the x-axis by the amount of overlap between different datasets.
Colored bars corresponding to their tissue types (Adipose, Artery, Heart, and
Skin) indicate that the particular eQTL was identified in the dataset, and white
space indicates that the eQTL was not found. The total number of replicating
eQTL are shown on the right. The black scale on the bottom right of each plot
shows the length covering 500 eQTL.
all datasets (839), and CONFETI-I (796), PANAMA (790), and CONFETI-P (780)
produced comparable results. While the number of replicating trans-eQTL only
showed minimal difference between methods, we found significantly more
trans-eQTL that replicated in all GTEx datasets. Additionally, unlike the results
in MuTHER dataset we found that many of the replicating trans-eQTL across
datasets consisted of genotype and gene pairs which were positioned on dif-
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ferent chromosomes (Figure B.11). However, more than 75% of the replicating
trans-eQTL were pseudogenes (Figure B.12). Therefore, the increase in trans-
eQTL replication in GTEx is likely driven by the additional genes measured by
RNA-seq and incomplete filtering of pseudogene relationships.
Figure 5.10: Replicating eQTL across all MuTHER datasets
Plots showing replicating eQTL for A.cis and B.trans-eQTL at an FDR threshold
of 0.01 across all methods (left) and the count of replicating eQTL versus
various FDR thresholds for each of the analysis methods (right). In the plots on
left, replicating eQTL are ordered on the x-axis by the amount of overlap
between methods. Colored bars corresponding to their method indicate that
the particular eQTL replicated, and the total number of replicating eQTL for
each method is shown at the end of each bar.
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5.3 Conclusion
In this chapter we presented the results of eQTL analysis conducted by apply-
ing CONFETI and other confounding factor correction methods to datasets ob-
tained from the MuTHER and GTEx consortium. We found that the application
of confounding factor correction methods largely increased the number of iden-
tified cis-eQTL in all analyzed datasets. Linear mixed model based methods
CONFETI-I, CONFETI-P, PANAMA, ICE, and PCAKMX also significantly in-
creased the number of identified trans-eQTL. To evaluate the quality of these
findings, we investigated replicating eQTL in both cis and trans categories as
performance measures. We found that linear mixed model based confounding
factor methods identified cis-eQTL that replicated well, with more than 60%
replicating in matched twin pairs in the MuTHER analysis, and that more than
40% replicating between similar tissue types in the GTEx analysis. However,
despite finding more trans-eQTL overall, the replication rate remained below
10% for eQTL identified with linear mixed model confounding factor correc-
tion methods. This trend could not be explained solely by smaller effect sizes of
trans-eQTL, since we would still expect part of the findings to replicate in twin
pairs. Thus, we concluded that the trans-eQTL findings are likely to be false
positives even at a relatively stringent FDR threshold of < 0.01.
Interestingly, we found little difference in both cis and trans-eQTL discovery
and replication between CONFETI-I, CONFETI-P, ICE and PANAMA. To our
surprise, the most conservative method ICE identified the largest number of
eQTL in most of the cases. This could illustrate that the contribution of genetic
effects to the total variance is not significant in human scale data, and account-
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ing for the majority of total variance is a good approximation of confounding
sample structures.
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APPENDIX OF CHAPTER 2
Figure A.1: Additional examples of gender specific expression patterns esti-
mated by ICA
Gender specific expression patterns estimated by ICA in a microarray dataset
of smokers and non-smokers (left) and the RNA-seq dataset from
GTEx-Skin-Sun-Exposed (right) showing the components with the most
significant association with the known covariate gender.
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Figure B.1: MuTHER and GTEx model fit 2
Additional genomic inflation factor plots.
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Figure B.2: Total Unique eQTL by Sample Size
The total number of eQTL identified by each method shown by sample size for
MuTHER and GTEx.
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Figure B.3: Significant eQTL discovered in MuTHER datasets for varying FDR
thresholds
Plots showing the counts of cis- and trans-eQTL versus a varying threshold of
FDR for each of the methods applied to every dataset.
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Figure B.4: Significant eQTL discovered in GTEx datasets for varying FDR
thresholds.
Plots showing the counts of cis- and trans-eQTL versus a varying threshold of
FDR for each of the methods applied to every dataset.80
Figure B.5: Replicating eQTL in the MuTHER LCL Subsets.
Figure B.6: Replicating eQTL in the MuTHER Skin Subsets.
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Figure B.7: Replicating eQTL between GTEx Heart Aorta and Tibial.
Figure B.8: Replicating eQTL between GTEx Heart Atrial Appendage and Left
Ventricle.
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Figure B.9: Replicating eQTL between GTEx Skin Leg and Skin Suprapubic.
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Figure B.10: Circos plots of replicating eQTL across all MuTHER datasets iden-
tified by each method.
Chromosomes are plotted in the outermost circles with replicating cis-eQTL
shown in gray bands within the next layer, and replicating trans-eQTL as blue
bands in the innermost layer where red lines connect each trans-eQTL to the
associated gene with gene annotations labeled in blue outside the circle.
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Figure B.11: Circos plots of replicating eQTL across all GTEx datasets identified
by each method.
Chromosomes are plotted in the outermost circles with replicating cis-eQTL
shown in gray bands within the next layer, and replicating trans-eQTL as blue
bands in the innermost layer where red lines connect each trans-eQTL to the
associated gene. Gene annotations were excluded due to space limits.
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Figure B.12: Gene annotations for replicating eQTL.
Bar plots showing the relative fraction of each gene annotation category in all
replicating cis and trans eQTL identified in A. MuTHER and B. GTEx.
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